Combining Zoledronic Acid and Fluvastatin for Breast and Ovarian Cancer Treatment
Author Information
Author(s): Louise A Knight, Christian M Kurbacher, Sharon Glaysher, Augusta Fernando, Ralf Reichelt, Susanne Dexel, Uwe Reinhold, Ian A Cree
Primary Institution: Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth, UK
Hypothesis
Can the combination of fluvastatin and zoledronic acid enhance anti-cancer effects in breast and ovarian cancer cells?
Conclusion
The combination of zoledronic acid and fluvastatin shows synergy against breast and ovarian cancer cells.
Supporting Evidence
- Both zoledronic acid and fluvastatin showed activity against breast and ovarian cancer in the ATP-based assay.
- The combination of the two drugs was more effective than either drug alone.
- Sequential drug experiments indicated that fluvastatin pre-treatment decreased sensitivity to zoledronic acid.
Takeaway
This study found that using two drugs together can work better to fight certain types of cancer than using them alone.
Methodology
The study tested 31 tumor samples using an ATP-based chemosensitivity assay to evaluate the effects of fluvastatin and zoledronic acid.
Limitations
The study was conducted in vitro, and results may not directly translate to clinical outcomes.
Participant Demographics
9 primary breast and 22 pre-treated ovarian carcinomas, median ages 50 and 58 respectively.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website